Biotechnology venture capital firm Ysios Capital has announced the closing of its second fund, Ysios BioFund II Innvierte FCR, which raised €126.4m and exceeded its initial target €100m.
Based in Barcelona, Spain, Ysios BioFund II Innvierte strengthened and expanded its investor base, attracting returning and new investors alike, and included institutional investors at national and international level. Amongst these were included the Spanish Ministry of Economy, the European Investment Fund (EIF) and the European Commission through InnovFin SME Venture Capital, a financial instrument developed under the EU Framework Programme for Research and Innovation Horizon 2020.
Carlos Moedas, European Commissioner for Research, Science and Innovation, said: “Thanks to the equity products developed under Horizon 2020, the EU today invests directly into some of Europe’s most promising companies in the biotech, medtech and diagnostic sectors. By providing finance for innovation in this way, we support the development of tomorrow’s healthcare solutions.”
Julia Salaverria of Ysios Capital Partners said: “We have exceeded our initial closing target. Ysios BioFund II Innvierte has become one of the biggest specialised biotechnology funds in southern Europe. We are very grateful to have the backing of many exceptional investors who have shown confidence in Ysios Capital’s work and in the potential of the biotechnology sector.”
Founded in 2008, Ysios Capital is an independent venture capital firm providing private equity financing for healthcare and biotechnology companies focusing on pharmaceuticals, diagnostics and medical devices.